Evidence map›Paper›PMID 41626173›Full record

ReviewFrontiers in oncology2025

The metabolic landscape of ovarian cancer stem cells: how do they survive?

Jixue Tan, Lin Tang, Qian Zhang

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jixue Tan *Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu, China.
Lin Tang *Emergency Obstetrics and Gynecology Department, West China Second University Hospital, Sichuan University, Chengdu, China.
Qian ZhangDepartment of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education (MOE), State Key Laboratory of Biotherapy, West China Second Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer remains one of the most lethal malignancies of the female reproductive system, with its high mortality rate largely driven by chemotherapy resistance and disease recurrence. Ovarian cancer stem cells (OCSCs), a small subpopulation within ovarian tumors, are characterized by their capacity for self-renewal, differentiation, and tumorigenic growth. They are recognized as central drivers of tumor initiation, metastasis, drug resistance, and relapse. Mounting evidence in recent years has highlighted the pivotal role of metabolic reprogramming in sustaining OCSC stemness and therapeutic resistance. In this review, we reported the major metabolic pathways engaged by cancer stem cells (CSCs), including glucose metabolism (glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation, and reactive oxygen species regulation), lipid metabolism, and amino acid metabolism. These pathways function to meet the bioenergetic and biosynthetic requirements of CSCs. Particular emphasis is placed on the metabolic plasticity of OCSCs, which can transform between a relatively inactive quiescent state and a highly proliferative active state. This adaptability allows OCSCs to respond dynamically to microenvironmental changes, facilitate ovarian cancer implantation and metastasis, and evade chemotherapeutic stress. We further analyze the molecular networks governing OCSC metabolism, including key signaling cascades and transcription factors. From a therapeutic perspective, we discuss the anti-diabetic drug metformin, which has demonstrated potential in targeting CSC metabolism in both preclinical models and clinical studies. Finally, we outline future research directions aimed at exploiting the metabolic vulnerabilities of OCSCs. We highlight that combination strategies targeting metabolism hold significant potential for overcoming treatment resistance and preventing ovarian cancer recurrence.

Indexed as

cancer metabolismcancer stem cellschemoresistancemetabolic plasticitymetastasisovarian cancer

Identifiers

PMID41626173
PMCPMC12855109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.